Stock Events

Stock Events

Avidity Biosciences

$72.86

63

+$0.04+0.05% Friday 15:01

Statistics

Day High

73.04

Day Low

72.75

52W High

73.06

52W Low

21.51

Volume

16,770,578

Avg. Volume

2,697,504

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

12MayExpected

Q4 2025

Q1 2026

-1.3

-1.3

-1.3

-1.29

Expected EPS

-1.294117

Actual EPS

N/A

Financials

-3,650.39%Profit Margin

Unprofitable

2020

2021

2022

2023

2024

2025

37.51MRevenue

-1.37BNet Income

Analyst Ratings

25.00Average Price Target

The highest estimate is 25.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Sarepta Therapeutics

Sarepta Therapeutics focuses on the discovery and development of RNA-targeted therapeutics, particularly for rare neuromuscular diseases, directly competing with Avidity's focus on RNA-based therapies.

Ionis Pharmaceuticals

Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a direct competitor in the RNA therapy space.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapies, targeting the same RNA-based therapeutic approach as Avidity.

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, using RNAi technology similar to Avidity's approach.

Moderna is focused on drug discovery and drug development based on messenger RNA (mRNA), competing in the broader RNA therapeutics field.

BioNTech SE works on individualized cancer medicine and other diseases using mRNA technology, making it a competitor in the RNA-based therapy market.

CRISPR Therapeutics

CRISPR Therapeutics is engaged in the development of gene-based medicines, including RNA-targeted therapies, placing it in competition with Avidity.

Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, indirectly competing in the genetic and RNA therapy space.

About

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Show more...

CEO

Ms. Sarah Boyce

Employees

511

Country

United States

Listings

0 Comments

Share your thoughts

FAQ

What is Avidity Biosciences stock price today?▼

The current price of RNAM is $72.86 USD — it has increased by +0.05% in the past 24 hours. Watch Avidity Biosciences stock price performance more closely on the chart.

What is Avidity Biosciences stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Avidity Biosciences stocks are traded under the ticker RNAM.

What is Avidity Biosciences revenue for the last year?▼

Avidity Biosciences revenue for the last year amounts to 37.51M USD.

What is Avidity Biosciences net income for the last year?▼

RNAM net income for the last year is -1.37B USD.

How many employees does Avidity Biosciences have?▼

As of September 04, 2026, the company has 511 employees.

In which sector is Avidity Biosciences located?▼

Avidity Biosciences operates in the Other sector.

When did Avidity Biosciences complete a stock split?▼

Avidity Biosciences has not had any recent stock splits.

Where is Avidity Biosciences headquartered?▼

Avidity Biosciences is headquartered in San Diego, United States.